SCHEMBL288560

SCHEMBL288560

CCOC(=O)CN(C)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11881268 0.98 CA12 (0.53)
SCHEMBL28014138 0.83
SCHEMBL3571272 0.81 CA12 (0.55)
SCHEMBL12589581 0.80 CA12 (0.59)
SCHEMBL196815 0.80
SCHEMBL5361760 0.79 GAA (0.54)
SCHEMBL13513410 0.79
Hydrochloric Acid SCHEMBL1876862 0.78 CA12 (0.57)
Hydrochloric Acid SCHEMBL8143027 0.78 CA12 (0.57)
SCHEMBL8632964 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3962317-A BACTERICIDES AMERICAN CYANAMID COMPANY (US) 1976-06-08 US claimed
CN-116768795-A Synthesis method of cyenopyrafen intermediate 湖南速博生物技术有限公司 2023-09-19 CN disclosed
CN-116554081-A Synthesis method of 3-phenyl-1-propyl-1H-isoindolecarboxylic acid 宿迁德威化工股份有限公司 2023-08-08 CN disclosed
EP-2427451-B1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CO LTD (JP) 2019-03-20 EP disclosed
EP-3441390-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS Ralexar Therapeutics, Inc. (US) 2019-02-13 EP disclosed
EP-2820013-B9 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS RALEXAR THERAPEUTICS INC (US) 2019-01-09 EP disclosed
US-20180305373-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO Prism BioLab Co., Ltd. (JP) 2018-10-25 US disclosed
US-10017522-B2 Alpha helix mimetics and methods relating thereto Prism BioLab Co., Ltd. (JP) 2018-07-10 US disclosed
US-20170334897-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions ALEXAR THERAPEUTICS, INC. 2017-11-23 US disclosed
US-20150368262-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO Prism BioLab Co., Ltd. (JP) 2015-12-24 US disclosed
EP-2427451-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BioLab Corporation (JP) 2012-03-14 EP disclosed
CN-102046628-A Alpha helix mimetics and methods relating thereto PRISM BIOLAB CORP 2011-05-04 CN disclosed
US-20110092459-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CORPORATION (JP) 2011-04-21 US disclosed
EP-2303887-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO Prism Biolab Corporation (JP) 2011-04-06 EP disclosed
WO-2010128685-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CORPORATION (JP) 2010-11-11 WO disclosed
WO-2010006944-A1 AMINOTETRAHYDROINDAZOLOACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-21 WO disclosed
WO-2009148192-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CORPORATION (JP) 2009-12-10 WO disclosed
EP-0002066-B1 2-ADAMANTYL HYDRAZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Teva Pharmaceutical Industries Limited (IL) 1983-05-25 EP disclosed
US-4254128-A 2-Adamantyl hydrazines and biocidal compositions thereof TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 1981-03-03 US disclosed
EP-0002066-A1 2-Adamantyl hydrazines and pharmaceutical compositions containing them Teva Pharmaceutical Industries Limited (IL) 1979-05-30 EP disclosed